1. Home
  2. AIRS vs DCTH Comparison

AIRS vs DCTH Comparison

Compare AIRS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIRS

AirSculpt Technologies Inc.

HOLD

Current Price

$4.67

Market Cap

328.7M

Sector

Health Care

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$12.41

Market Cap

372.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRS
DCTH
Founded
2012
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
328.7M
372.5M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
AIRS
DCTH
Price
$4.67
$12.41
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$22.00
AVG Volume (30 Days)
449.6K
379.0K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
N/A
N/A
Revenue
$151,818,000.00
N/A
Revenue This Year
$5.19
$24.54
Revenue Next Year
$5.32
$33.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.51
$8.12
52 Week High
$12.00
$13.74

Technical Indicators

Market Signals
Indicator
AIRS
DCTH
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
AIRS
DCTH

About AIRS AirSculpt Technologies Inc.

AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: